未知股票 LIPO 深 沪
已收盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 462.08万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Caplin Point Buys $473 Million Portfolio of US-Approved Injectable and Ophthalmic ANDAs
Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) has shared an update. Ca...
01-01 14:12
BRIEF-Lipocine Highlights Promising Interim Safety Profile In Phase 3 Trial Of Lpcn 1154 In Postpartum Depression (Ppd)
Lipocine Inc LPCN.O: LIPOCINE HIGHLIGHTS PROMISING INTERIM SAFETY PROFILE IN PHASE 3 TRIAL OF LPCN 1154 IN POSTPARTUM DEPRESSION (PPD) LIPOCINE INC: TOPLINE RESULTS ARE ON TRACK FOR Q2 OF 2026 LIPOCIN...
2025-11-18 21:16
BRIEF-Lipocine Provides Progress Update On LPCN 1154 Phase 3 Clinical
Sept 30 (Reuters) - Lipocine Inc LPCN.O: LIPOCINE PROVIDES PROGRESS UPDATE ON LPCN 1154 PHASE 3 CLINICAL TRIAL IN POSTPARTUM DEPRESSION (PPD) LIPOCINE INC: DSMB SAFETY REVIEW UPDATE PLANNED FOR 4Q 202...
2025-09-30 21:54
BRIEF-Lipella Pharmaceuticals Announces Positive Final Results From Phase 2a Study Of LP-10 In Oral Lichen Planus
Sept 18 (Reuters) - Lipella Pharmaceuticals Inc LIPO.PK: LIPELLA PHARMACEUTICALS ANNOUNCES POSITIVE FINAL RESULTS FROM PHASE 2A STUDY OF LP-10 IN ORAL LICHEN PLANUS Source text: ID:nGNX2Bvgjq Further ...
2025-09-18 20:10
BRIEF-Lipocine Doses First Patient in Phase 3 Trial for LPCN 1154 in Postpartum Depression
June 26 (Reuters) - Lipocine Inc LPCN.O: LIPOCINE ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 CLINICAL TRIAL FOR LPCN 1154 IN POSTPARTUM DEPRESSION LIPOCINE INC - PHASE 3 TOP LINE RESULTS EXPECTED Q2 202...
2025-06-26 20:03
BRIEF-Lipella Pharmaceuticals Announces Delisting From Nasdaq Capital Market
June 20 (Reuters) - Lipella Pharmaceuticals Inc LIPO.PK: LIPELLA PHARMACEUTICALS ANNOUNCES DELISTING FROM NASDAQ CAPITAL MARKET LIPELLA PHARMACEUTICALS INC - DELISTING DUE TO NON-COMPLIANCE WITH NASDA...
2025-06-21 03:44
Lipella Pharmaceuticals Granted U.S. Patent For MRI-Based Detection Method For Interstitial Cystitis, Titled "Systems And Methods Of Detecting Interstitial Cystitis" Extending Protection Through 2045
Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced the issuance of
2025-06-17 20:38
Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology
Pittsburgh, June 17, 2025: Lipella Pharmaceuticals Inc. announced the issuance of U.S. Patent No. 12,326,492, covering a MRI-based method to detect lesions in body cavities. This专利 strengthens Lipella's strategic position in drug delivery and enhances the monitoring and early detection of diseases like mucosal disorders and bladder cancer. The non-invasive MRI contrast agent technology will support Lipella's clinical development programs, includi...
2025-06-17 12:30
隆利科技：南方基金、信达证券等多家机构于6月9日调研我司
证券之星消息，2025年6月10日隆利科技（300752）发布公告称南方基金吴春林、信达证券杨宇轩 赵晓晗、东方基金梁忻、五地基金刘晶、方正证券徐凡、平安基金季清斌 黄维、诺安基金黄友文于2025年6月9日调研我司。
2025-06-11 09:31
BRIEF-Lipocine Announces Filing Of New Drug Submission For TLANDO In Canada
June 9 (Reuters) - Lipocine Inc LPCN.O: LIPOCINE ANNOUNCES FILING OF NEW DRUG SUBMISSION FOR TLANDO® IN CANADA Source text: ID:nPn6zM1DTa Further company coverage: LPCN.O ((Reuters.Briefs@thomsonreute...
2025-06-09 20:37
